IMMUNE Program by BIODRIP

BIO DRIP
- ANTIAGING & REGENERATIVE MEDICINE -

🔬 Backed by 30+ Years of Scientific Research

📖 160+ Clinical Studies Since 1993

Neurological & Developmental Disorders

- ALS, Autism, Alzheimer's, Parkinson's, MS

Cancer Types

- Brain, Breast, Bladder, Colorectal, Prostate, Pancreatic, Liver, Lung, Kidney, Ovarian, Larynx, Tongue, Melanoma, Multiple Myeloma, etc.

Infectious & Immune Conditions

- HIV/AIDS, Epstein-Barr Virus, Herpes Simplex, Lyme Disease, COVID-19, Chronic Fatigue Syndrome, Inflammatory Bowel Disease, Endometriosis, COPD, SLE

🧠 Scientifically Validated Effects

- Activates macrophages that kill cancer cells
- Inhibits angiogenesis (limits tumor blood supply)
- Reduces cancer cell proliferation and metastasis
- Reverts cancer cells into non-cancerous phenotype
- Induces apoptosis (programmed cell death)
- Suppresses HER2 oncogene expression
- Repairs neurons and promotes neurogenesis

- Increases mitochondrial energy production
- Regulates endocannabinoid gene expression
- Stimulates nitric oxide release
- Counteracts chemotherapy-induced neuropathy
- Stimulates bone resorption through osteoclast activation

🧩 Role in Integrative Cancer Care

- May reduce recurrence after conventional cancer treatments
- Shown effective in undifferentiated tumors
- Less effective in hematologic cancers (e.g., leukemia)
- Not suitable for anemic patients

📚 Research & References

1. **Saburi et al. (2017) – α-N-acetylgalactosaminidase and cancer**
   https://pubmed.ncbi.nlm.nih.gov/29332325/
2. **Thyer et al. (2013) – GcMAF and α-N-acetylgalactosaminidase in cancer**
   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3812199/
3. **Saburi et al. (2017) – Role of Gc-MAF in cancer immunotherapy**
   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686300/
4. **Albracht (2022) – Critical review of Yamamoto's research**
   https://www.sciencedirect.com/science/article/pii/S2468294222000284
5. **Morucci et al. (2015) – GcMAF and neuronal damage**
   https://pubmed.ncbi.nlm.nih.gov/25304987/

6. **Mohammed et al. (2014) – Infections and antibiotics in terminal cancer**
https://pubmed.ncbi.nlm.nih.gov/25150130/

7. **Kanda et al. (2002) – GcMAF effects on angiogenesis**
https://academic.oup.com/jnci/article/94/17/1311/2519874

8. **Yamamoto et al. (2008) – Prostate cancer immunotherapy**
https://www.sciencedirect.com/science/article/pii/S1936523308800083

9. **Smith et al. (2013) – GcMAF and chronic fatigue**
https://arpi.unipi.it/handle/11568/1053382

10. **Siniscalco et al. (2014) – GcMAF and endocannabinoid regulation in autism**
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3996516/

11. **Tobinick et al. (2006) – TNF-alpha in Alzheimer's**
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1785182/

12. **Greilberger et al. (2017) – Vitamin D & oxidative stress in ALS**

https://www.oatext.com/measurement-of-oxidative-stress-parameters-vitamin-d-and-vitamin-d-binding-protein-during-vitamin-d-treatment-in-a-patient-with-amyotrophic-lateral-sclerosis.php